金宇生物技术股份有限公司修订回购注销2023年员工持股计划部分股票数量公告
要点摘要
- 公司董事会于2026年4月22日召开会议，审议并通过了关于回购注销2023年员工持股计划部分股票及修订公司章程的议案。
- 因相关人员变动，经核查后，公司对2023年员工持股计划拟回购注销股票数量进行了修订。
- 回购注销的主要原因是员工持股计划第三个解锁期公司层面业绩考核未达成，以及11名持有人因离职失去持股计划资格。
- 回购注销的股票数量从原公告的906.89万股修订为851.84万股，回购价格为6.23元/股。
- 同时，公司拟注销回购专用证券账户中使用期限满三年的回购股份330.16万股。
- 本次注销后，公司注册资本及股份总数将减少。具体由人民币1,111,747,826元、股份总数1,111,747,826股，分别变更为1,099,927,826元和1,099,927,826股。
- 公司章程相关条款同步修订，需提交股东大会审议。
对股东及投资者的影响
- 股份总数减少：本次回购注销和股份注销将导致公司总股本减少约1,182万股，股份总数下降至1,099,927,826股。股份数量变动可能会影响每股收益、每股净资产等财务指标。
- 业绩考核未达成：员工持股计划第三个解锁期业绩考核未达成，反映公司业绩未能达到此前设定目标，可能对市场信心有一定影响。
- 离职影响持股计划：11名员工因离职失去持股资格，相关股份也被回购注销，显示公司人员流动对持股计划产生直接影响。
- 回购价格与市场价格关系：回购价格为6.23元/股，投资者可关注该价格与市场价格差异，评估公司回购行为对股价的影响。
- 公司章程修订：注册资本和股份总数的调整将体现在公司章程中，需经股东大会审议，最终以中国证券登记结算公司登记为准。
- 信息披露合规：公司已在上海证券交易所网站进行信息披露，保证公告内容真实、准确、完整。
详细内容
金宇生物技术股份有限公司董事会于2026年4月22日召开第十二届董事会第五次会议，审议通过了《关于拟回购注销2023年员工持股计划部分股票及注销回购专用证券账户中部分股票的议案》、《关于修订公司章程及其他制度的议案》。公司于2026年4月23日在上海证券交易所网站披露相关公告。因相关人员变动，公司对回购注销数量进行了修订。
修订后的公告显示，2023年员工持股计划首次授予部分第三个解锁期解锁条件未成就，对应标的股票851.84万股予以回购注销，回购价格为6.23元/股。同时，公司回购专用证券账户中使用期限满三年的回购股份330.16万股也将一并注销。本次注销后，公司注册资本由人民币1,111,747,826元减少至1,099,927,826元，股份总数由1,111,747,826股减少至1,099,927,826股。公司章程的第六条和第二十条同步修订，需提交公司股东大会审议。
此外，原公告及上网文件的其他内容保持不变，最终股本结构变动以中国证券登记结算有限责任公司上海分公司出具的证券变更登记表为准。
投资者须关注事项
- 公司股份总数减少，可能影响公司估值及市场表现。
- 业绩考核未达成信息具有敏感性，需关注对股价影响。
- 回购价格与市场价格的对比，投资者可据此评估公司回购政策合理性。
- 股东大会决议及最终登记结果将决定股本结构最终变动。
免责声明
本文仅供参考，不构成投资建议。投资者应根据自身风险偏好及市场情况作出决策。公告内容以公司正式发布及证券登记结算公司登记结果为准。
Jinyu Biological Technology Co., Ltd. Revises Buy-back and Cancellation Quantity of 2023 Employee Stock Ownership Plan Shares
Key Highlights
- The Board held a meeting on April 22, 2026, approving proposals to buy back and cancel part of the 2023 employee stock plan shares and amend the company charter.
- Due to personnel changes, the company revised the number of shares to be repurchased and cancelled for the 2023 ESOP.
- The main reasons for the buy-back and cancellation are the failure to meet performance targets in the third unlocking period and 11 holders losing ESOP eligibility due to resignation.
- The number of shares to be cancelled has been revised from 9.0689 million to 8.5184 million shares, with a buy-back price of RMB 6.23 per share.
- Additionally, 3.3016 million shares from the dedicated buy-back account, held for three years, will also be cancelled.
- After cancellation, registered capital and total shares will decrease: from RMB 1,111,747,826 (total shares: 1,111,747,826) to RMB 1,099,927,826 (total shares: 1,099,927,826).
- Relevant clauses in the company charter will be revised and submitted to the shareholders’ meeting for approval.
Implications for Shareholders and Investors
- Reduction in Total Shares: The repurchase and cancellation will reduce total shares by approximately 11.82 million, impacting per-share metrics such as EPS and NAV.
- Performance Target Not Achieved: Failure to meet ESOP performance targets suggests the company did not reach set goals, which may affect market confidence.
- Personnel Impact: 11 employees lost ESOP eligibility due to resignation, showing how personnel changes affect the ESOP.
- Repurchase Price: The buy-back price is RMB 6.23 per share. Investors should monitor the relationship between this price and the market price for impact assessment.
- Charter Amendments: Changes to registered capital and total shares will be reflected in the company charter, subject to shareholder approval and final registration.
- Regulatory Compliance: The company has disclosed information on the SSE website, ensuring transparency and completeness.
Detailed Content
Jinyu Biological Technology Co., Ltd. Board convened on April 22, 2026, approving the repurchase and cancellation of part of the 2023 ESOP shares and amendments to the company charter. The company disclosed relevant announcements on April 23, 2026, on SSE’s website. After personnel changes, the number of shares to be repurchased and cancelled was revised.
The revised announcement states that due to the failure to meet performance targets in the third unlocking period, 8.5184 million shares will be repurchased and cancelled at RMB 6.23 per share. Additionally, 3.3016 million shares from the buy-back account, held for three years, will also be cancelled. After cancellation, registered capital will decrease from RMB 1,111,747,826 to RMB 1,099,927,826; total shares will decrease from 1,111,747,826 to 1,099,927,826. Relevant charter clauses will be revised and submitted for shareholder approval.
Other contents of the original announcement remain unchanged. The final change in share structure will be subject to the registration result by China Securities Depository and Clearing Corporation Shanghai Branch.
Investor Focus
- Reduction in total shares may affect company valuation and market performance.
- Performance target result is sensitive and may influence share price.
- Compare repurchase price to market price for policy assessment.
- Shareholder meeting resolutions and registration results will determine final share structure.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should make decisions based on their own risk preferences and market conditions. Official announcement and registration results by the securities depository and clearing company shall prevail.
